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incidence
The incidence of malignant melanoma varies from 3–5/
100 000/year in Mediterranean countries to 12–20 in Nordic
countries and is still rising. The mortality rate is 2–3/100 000/
year with a lesser variation with geography and relatively stable
over the last decade. However, the melanoma mortality rate in
males but not in females has increased over the last 25 years.
Increased ultraviolet light exposure of a genetically predisposed
population seems to be at least in part responsible for an
ongoing increase in incidence over recent decades.
diagnosis
Suspicious lesions are characterized by Asymmetry, Border
irregularities, Colour heterogeneity, Dynamics (dynamics in
colours, elevation or size) (‘ABCD rule’). Today, many primary
melanomas have a diameter of <5 mm). Dermoscopy by an
experienced physician enhances the diagnostic accurancy [B].
Diagnosis should be based on a full thickness excisional
biopsy with a small side margin. Processing by an experienced
pathology institute is mandatory.
The histology report should follow the AJCC classification
and includes the maximum thickness in millimeters (Breslow),
level of invasion (Clark level I–V), presence of ulceration,
presence and extent of regression and clearance of the surgical
margins. However, in due time the evaluation of the Clark level
is being omitted and replaced by information on the mitotic
rate of the primary tumour.
staging
Physical examination with special attention to other suspicious
pigmented lesions, tumour satellites, in-transit metastases,
regional lymph node and systemic metastases is mandatory.
In low-risk melanomas (tumour thickness <1 mm) no other
investigations are necessary. In higher stages imaging is
recommended in order to allow proper staging.
The refined version of the AJCC staging and classification
system which includes a sentinel node staging is the only
internationally accepted classification system (Table 1).
treatment of localized disease
Wide excision of primary tumours with safety margins of
0.5 cm for in situ melanomas, of 1 cm for tumours with
a Breslow thickness up to 2 mm and 2 cm for thicker tumours
is recommended [II, B]. Modifications may be needed for
preservation of function in acral and facial melanomas.
Routine elective lymphadenectomy or irradiation to the
regional lymph nodes is not recommended [II, B].
Sentinel lymph node biopsy in melanoma with a tumour
thickness of >1 mm is necessary for precise staging. It should be
followed by a complete lymphadenectomy of regional lymph
nodes, if the sentinel node was found positive for metastases
[C]. However, this procedure has no proven effect on overall
survival. Sentinel lymph node biopsy should be performed only
by skilled teams in experienced centres.
There is no generally accepted adjuvant therapy to date for
patients with high-risk primary melanoma (stage IIB/C) or
completely resected lymph node metastases (stage III).
A number of prospective randomized trials have investigated
adjuvant treatment with low, intermediate and high doses of
interferon (IFN)-a. IFN-a therapy following the resection of the
primary tumour has improved recurrence-free survival (RFS),
but without confirmed significant effects on overall survival (OS).
The first trial that showed a positive effect in OS was ECOG
1684: 287 patients were enrolled to receive high-dose IFN-a for 1
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year versus observation. Twenty-five per cent of the patients had
to be withdrawn due to severe adverse effects. Five-year disease-
free survival (FS) was 37% versus 26% and OS was 46% versus
37%. On this basis, high-dose adjuvant IFN-a won US FDA
approval. A meta-analysis of several high-dose interferon trials
showed no statistically significant effect on OS. It was then
proposed that IFN might exert its best effect in long-term therapy.
Since PegIFN-a is suitable for long-term therapy, the
European Organisation for Research and Treatment of Cancer
(EORTC) has designed a large prospective randomized trial to
investigate the potent positive effect of PegIFNa-2b in the
adjuvant setting in patients with stage III melanoma. A total of
1256 patients with resected stage III melanoma were
randomized to receive observation or pegylated IFN-a therapy.
Randomization was stratified for microscopic (N1) versus
macroscopic (N2) nodal involvement, number of positive
nodes, ulceration and tumour thickness. RFS (primary
endpoint), distant-metastases-free survival (DMFS) and OS
were analysed for the intent-to-treat population.
The interferon group received an induction interferon dose
of a weekly dose of 6 lg/kg for the first 8 weeks and then the
dose was reduced to 3 lg/kg per week for 5 years.
At 3.8 years of median follow-up, RFS was significantly
reduced by 18% in the PegIFNa-2b arm compared with
observation; the 4-year RFS rate was 45.6% compared with
38.9%. DMFS was improved but non-significantly (P = 0.11).
OS was unchanged in the two groups. In stage III-N1a (micro-
metastases detected in the sentinel node) both RFS [hazard
ratio (HR) 0.72; 57.7%vs 45.4%; P = 0.01] and DMFS (HR
0.73; 60.5% versus 52.6%; P = 0.01) were prolonged in the
PegIFNa-2b arm, whereas in stage III-N1b (macroscopic
metastases) there was no benefit.
This trial showed that a prolonged adjuvant treatment with
IFN-a improved the RFS period and DMFS in a subgroup of
patients with low tumour burden.
Therefore, in this patient population pegylated interferon can
be recommended, if the individual patient tolerates it well [C].
Adjuvant treatment in patients with resected macroscopic node
involvement is preferentially applied in the context of
randomized clinical trials in specialized centres. However, high-
dose interferon a2b is an approved indication for this
therapeutic situation.
Adjuvant chemotherapies, mistletoe (Viscum album) extracts,
and hormone therapies are not beneficial. Adjuvant
immunotherapy with other cytokines including interleukin-2,
tumour vaccination, and immunochemotherapy is
experimental and not to be used outside of controlled clinical
trials.
Radiotherapy for local tumour control should be considered
in case of inadequate resection margins of lentigo maligna
melanoma or R1 resections of melanoma metastases when
surgery is not feasible [B].
treatment of locoregional metastatic
disease
In the case of isolated loco-regional lymph node metastases,
surgical removal, including the surrounding lymph node
region, is indicated; removal of the tumour-bearing lymph
node alone is insufficient. Surgical removal is also
recommended in the case of an single metastasis in
parenchymal organs, including the central nervous system.
However, before undertaking additional aggressive local
surgical treatments, a detailed staging investigation, including
Table 1. AJCC Staging system of melanoma
Stage Primary tumour (pT) Regional lymph node metastases (N) Distant metastases (M)
0 In situ tumour None None
IA £1.0 mm, no ulceration None None
IB £1.0 mm with ulceration or Clark Level
IV or V
None None
1.01–2.0 mm, no ulceration None None
IIA 1.01–2.0 mm with ulceration None None
2.01–4.0 mm, no ulceration None None
IIB 2.01–4.0 mm with ulceration None None
>4.0 mm, no ulceration None None
IIC >4.0 mm with ulceration None None
IIIA Any tumour thickness, no ulceration Micrometastases None
IIIB Any tumour thickness with ulceration Micrometastases None
Any tumour thickness, no ulceration Up to three macrometastases None
Any tumour thickness6ulceration None but satellite and/ or in-transit
metastases
None
IIIC Any tumour thickness with ulceration Up to three macrometastases None
Any tumour thickness6ulceration Four or more macrometastases, or
lymph node involvement extending
beyond capsule, or satellite and/or
in-transit metastases with lymph
node involvement
None
IV Distant metastases
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imaging techniques such as CT or PET (positron emission
tomography) scans, is necessary to exclude the presence of
further metastases [B].
Non-resectable in-transit metastases or inoperable primary
tumours of the limbs without additional metastases may be
treated with isolated limb perfusion using e.g. melphalan and/
or tumour necrosis factor alpha [II-III, C]. However, such
treatment requires major surgery and should be restricted to
centres of excellence. Radiation therapy may be used
alternatively [V, D], although there are no data showing
a positive effect on any outcome measure.
treatment of systemic metastatic
disease
(stage IV; AJCC classification from 2002)
Patients should preferentially be treated within clinical trials.
However, not for all metastasized melanoma patients clinical
trials are available. In these cases palliative therapy for advanced
disease with several metastases in different anatomical regions
may initially use well tolerated cytostatics such as dacarbazine
(DTIC), taxanes, fotemustine or others, cytokines (Interferons,
Interleukin-2) or combinations. There is no standard therapy.
However dacarbazine is at least considered as a reference drug
in this situation. In aggressive metastastic disease multi-agent
polychemotherapy [C] containing Paclitaxel and Carboplatin
or Cisplatin, Vindesine and Dacarbazine produce partial
response and stabilizations in a meaningful number of patients.
However, since the overall impact of systemic therapy on
survival in advanced melanoma patients is questionable, these
patients should be preferentially treated in controlled clinical
trials evaluating new treatment modalities.
There are no randomized clinical trials for IL2 monotherapy.
Some centres still today use IL2 as first line therapy when
disease burden is low. Several randomized trials did not show
any survival benefit for the very intensive biochemotherapy
including IL-2. Over the last decades several phase II clinical
trials have demonstrated the feasibility of CTLA4 blockade
either alone or in combination with vaccines or chemotherapy.
These therapeutic approaches using CTLA4 blockade have
resulted in a proportion of metastatic melanoma patients
surviving up to two years and longer. These results are
promising. However, they have to be confirmed by randomized
phase III clinical trials (Table 2).
Surgery of visceral metastases may be appropriate for selected
cases with good performance status and isolated tumour
manifestations. In principal, the goal are R0-resections in these
patients.
Palliative radiotherapy should be considered especially for
symptomatic brain or localized and painful bone metastases.
In general, stage IV melanoma patients need to be treated
and discussed in an interdisciplinary tumour board at centres
with broad experience in this disease.
patient information and follow-up
Melanoma patients should be instructed in avoidance of
sunburns, extended unprotected solar or artificial ultraviolet
exposure and in lifelong regular self-examinations of the skin
and peripheral lymph nodes. Patients must be aware that family
members have an increased melanoma risk [B].
During melanoma follow-up, patients are clinically
monitored in order to detect a relapse and to recognize
additional skin tumours, especially secondary melanomas, as
Table 2. Treatment modalities for melanoma metastases
Number and localization of the metastases Treatment modalitiesa Grade of recommendation
In-transit metastases (few) (pTXN2cM0) 1. Surgical removal C
2. Radiotherapy C
In-transit metastases (multiple, >5) (pTXN2cM0) 1. Perfusion of the extremityb DD
2. Radiotherapy (systemic chemoimmunotherapy)b D
Locoregional lymph nodes (pTxN1a,2a) 1. Consider trial participation
2. Additional Interferon alpha treatment1 B
Locoregional lymph nodes (pTxN2b,2c,3) 1. Radical lymphadenectomy, in case of incomplete
resection: irradiation,
C
2. Consider trial participation C
Solitary central nervous system metastases
(pTxNxM3)
1. Neurosurgical removal D
2. Stereotactic irradiationb (according to localization
this could also be the 1st choice)
D
Solitary lung metastases (pTxNxM1) 1. Surgical removal D
2. Consider clinical trial participation
3. Chemotherapy/immunotherapyb D
Multiple metastases (pTxNxM1a-1c) 1. Consider clinical trial participation
2. Chemotherapy / immunotherapyb
Painful bone metastases (pTxNxM1a-1c) 1. Consider clinical trial participation D
2. Radiotherapy C
aGiven as 1st choice, 2nd choice and 3rd choice.
bThese therapies should be restricted to controlled studies at specialized centres.
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early as possible [B]. However, it is unknown if this policy leads
to improved survival rates. Eight per cent of all melanoma
patients develop a secondary melanoma within 2 years of their
initial diagnosis. Melanoma patients also have increased risks
for other skin tumours. In patients with lentigo maligna
melanomas, 35% of the patients developed another cutaneous
malignancy within 5 years.
There is currently no consensus on the frequency of follow-
up and the use of imaging techniques. In recent series, most
relapses have been detected by the patients themselves,
questioning the usefulness and cost-effectiveness of follow-up
visits every 3 months during the first 3 years and every 6–12
months thereafter. Above recommendations were solely based
on the relapse-risk profile over time. Increased intervals
between controls may reduce false positive findings and suffice
for psychological support of the patients.
Since patients with a thin primary melanoma have only
a small risk of relapse, routine imaging techniques are
definitively not necessary for this patient population. In high
risk patients, e.g. those with thick primary tumours or
following treatment of metastases ultrasound of lymph nodes,
CT or whole body PET/PET-CT scans may lead to an earlier
diagnosis of regional or systemic relapses. However, an impact
of radiological exams upon survival has not been demonstrated
so far. Rising serum S-100 has a higher specificity for disease
progression than LDH and therefore is the most accurate blood
test in the follow-up of melanoma patients if any blood test is
recommended at all [D].
note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts.
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